Sorrento has had a long journey from a humble beginning to a diversified biopharma discovering and developing life changing medicine.
Acquired Resiniferatoxin (RTX) assets via the acquisition of Sherrington Pharmaceuticals Inc.
Acquired Antibody Drug Conjugation (ADC) technologies via acquisition of Concortis Biosystems Corp.
Out-licensed PD-L1 for Greater China market to Lee’s Pharm
In-licensed Erbitux®, Remicade®, Xolair®, Simulect® biosimilar candidates from Mabtech Limited
Formed ImmuneOncia JV with Yuhan Pharmaceuticals
Acquired ZTlido® via majority stake in Scilex Pharmaceuticals
Acquired Bioserv Corporation for cGMP manufacturing operations
Formed Levena Suzhou Biopharma Co. LTD for Antibody Drug Conjugation (ADC) services
Acquired Oncolytic Virus platform via the acquisition of Virttu Biologics Limited
Formed Celularity with Celgene and United Therapeutics
Acquired Sofusa® Lymphatic Delivery System from Kimberly-Clark
Acquired Semnur Pharmaceuticals
Formed Scilex Holding to consolidate the merger of Scilex Pharma and Semnur Pharma
Established CBD JV with LifeTech Scientific